Amgen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw
- Conditions
- Solid TumoursBone Metastasis
- Interventions
- Other: Physician Survey
- First Posted Date
- 2013-12-02
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 420
- Registration Number
- NCT01998607
TRANSFORM - Observational Cohort Study of Darbepoetin Alfa Use in European Union (EU) Hemodialysis Patients Switched From PEG Epoetin Beta
- Conditions
- Anemia
- First Posted Date
- 2013-11-28
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1027
- Registration Number
- NCT01997892
- Locations
- 🇨🇭
Research Site, Sion, Switzerland
Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis
- Conditions
- Postmenopausal Osteoporosis (PMO)
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2019-03-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 252
- Registration Number
- NCT01992159
- Locations
- 🇯🇵
Research Site, Toshima-ku, Tokyo, Japan
AMG 386 Drug-Drug Interaction Study With Paclitaxel
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2014-09-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 35
- Registration Number
- NCT01992341
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States
Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer
- Conditions
- Extensive-Stage Small-Cell Lung Cancer
- Interventions
- First Posted Date
- 2013-11-19
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 32
- Registration Number
- NCT01987232
- Locations
- 🇷🇺
State Budgetary Healthcare Institution of Yaroslavl Region "Regional Clinical Oncological Hospital", Yaroslavl, Russian Federation
🇺🇸Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
🇷🇺Regional Budgetary Healthcare Institution "Kursk Regional Clinical Oncology Dispensary", Kislino, Kursk, Russian Federation
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3
- Conditions
- Hyperlipidemia
- Interventions
- Other: Placebo to EzetimibeOther: Placebo to Evolocumab
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2018-11-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 511
- Registration Number
- NCT01984424
- Locations
- 🇬🇧
Research Site, Newcastle upon Tyne, United Kingdom
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2013-11-11
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 22
- Registration Number
- NCT01980589
- Locations
- 🇺🇸
James R. Berenson, MD, West Hollywood, California, United States
🇺🇸California Cancer Associates for Research and Excellence, Encinitas, California, United States
🇺🇸The Oncology Institute of Hope and Innovation, Whittier, California, United States
Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis
- Conditions
- Psoriasis
- Interventions
- Biological: ABP 501Biological: Adalimumab
- First Posted Date
- 2013-10-28
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- Amgen
- Target Recruit Count
- 350
- Registration Number
- NCT01970488
- Locations
- 🇭🇺
Research Site, Nyíregyháza, Szabolcs-szatmar-bereg, Hungary
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Biological: AdalimumabBiological: ABP 501
- First Posted Date
- 2013-10-28
- Last Posted Date
- 2016-12-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 526
- Registration Number
- NCT01970475
- Locations
- 🇬🇧
Research Site, Cardiff, Wales, United Kingdom
Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA™ or Zoledronic Acid
- Conditions
- Osteonecrosis of the JawInfection Leading to Hospitalization
- First Posted Date
- 2013-10-22
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 2560
- Registration Number
- NCT01967160